#Astellas #pancreaticcancer #Vyloy #zolbetuximab #claudin182targetingcancerdrug #GLEAMstudy #metastaticpancreaticadenocarcinoma #GLEAMtrial #pancreaticcancerresearch #claudin182targetedtherapy #CLDN182testing #GanymedPharma #ESMO #GEJcancer #biopharma
zurl.co/DtTYd
zurl.co/DtTYd
Astellas suffers pancreatic cancer failure with Vyloy
Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.
zurl.co
October 16, 2025 at 10:17 AM
Everybody can reply
A year ago, #Astellas was celebrating the first-in-class approval of its #claudin 18.2-targeting cancer drug Vyloy for gastric cancers. Now, a bid to expand its label into #pancreaticcancer has hit the buffers.
pharmaphorum.com/news/astella...
pharmaphorum.com/news/astella...
October 14, 2025 at 8:56 AM
Everybody can reply
アステラス製薬によるガニメド(Ganymed Pharmaceuticals)買収の話も出てきて、調べてみると€422百万の一時金+最大€860百万の成果連動支払で、その後、胃がん治療薬ビロイ(VYLOY, ゾルベツキシマブ)は商品化に成功し売り上げが拡大してるけど、買収額が巨額過ぎたのか、24年度第3四半期決算で株式減損処理で606億円の特別損失を計上。
www.mixonline.jp/tabid55.html...
www.mixonline.jp/tabid55.html...
mRNAワクチンの衝撃 ―コロナ制圧と医療の未来―
ファイザー社と組み、11カ月という常識外のスピードで世界初の新型コロナワクチンの開発に成功したドイツ・ビオンテック社。画期的なmRNA技術で一躍注目を集めるバイオ企業の創業者/研究者夫妻に密着、熾烈な…
www.hayakawa-online.co.jp
September 29, 2025 at 11:58 PM
Everybody can reply
アステラス製薬によるガニメド(Ganymed Pharmaceuticals)買収の話も出てきて、調べてみると€422百万の一時金+最大€860百万の成果連動支払で、その後、胃がん治療薬ビロイ(VYLOY, ゾルベツキシマブ)は商品化に成功し売り上げが拡大してるけど、買収額が巨額過ぎたのか、24年度第3四半期決算で株式減損処理で606億円の特別損失を計上。
September 30, 2025 at 12:14 AM
Everybody can reply
Claudin 18.2: Pioneering Advances in Oncology Therapeutics with Blockbuster Potential#None#oncology#VYLOY#Claudin_18.2
Claudin 18.2: Pioneering Advances in Oncology Therapeutics with Blockbuster Potential
DelveInsight's analysis reveals the resurgence of Claudin 18.2-directed therapies in oncology, projecting significant growth and transformative impact on cancer treatments by 2034.
third-news.com
July 23, 2025 at 9:44 PM
Everybody can reply
"Astellas Korea renews bid to reimburse targeted gastric cancer drug Vyloy"
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
Astellas Korea renews bid to reimburse targeted gastric cancer drug Vyloy
Astellas Korea will reapply for health insurance coverage for its new drug Vyloy (zolbetuximab), a targeted treatment for Claudin 18.2 gastric cancer.Earlier this month, Astellas Korea submitted an application to the health insurance authorities for coverage of Vyloy. The reapplication comes about f
www.koreabiomed.com
July 11, 2025 at 5:01 AM
Everybody can reply
'Vyloy took targeted treatment for stomach cancer to higher level’
The landscape of cancer-targeted therapies is changing. A new target called Claudin18.2 (CLDN18.2) has emerged in the treatment of metastatic gastric cancer, which has long relied on targeting HER2 alone. This greatly expands the number of patients who can benefit from targeted therapies.The first d
www.koreabiomed.com
June 18, 2025 at 9:59 PM
Everybody can reply
‘Have we no shame?’ Federal judge declares NIH grant terminations ‘void and illegal.’
This is a strong affirmation that gov't cannot arbitrarily cut research funding based on political or ideological criteria, and that sci research must be allowed to proceed based on its merit.
archive.ph/vyLOy
This is a strong affirmation that gov't cannot arbitrarily cut research funding based on political or ideological criteria, and that sci research must be allowed to proceed based on its merit.
archive.ph/vyLOy
archive.ph
June 16, 2025 at 8:55 PM
Everybody can reply
6 likes
Astellas Receives NMPA Approval for VYLOY™ as Leading Treatment for Advanced Gastric Cancer#China#Tokyo#gastric_cancer#Astellas#VYLOY
Astellas Receives NMPA Approval for VYLOY™ as Leading Treatment for Advanced Gastric Cancer
Astellas Pharma's VYLOY™ (zolbetuximab) is now approved in China for treating advanced gastric cancer, offering hope to many patients.
third-news.com
January 6, 2025 at 12:03 AM
Everybody can reply
«Astellas получает одобрение Европейской комиссии для VYLOY в борьбе с.advance стадиями рака желудка»
https://kripta.biz/posts/198E0B2C-018C-41F6-89F7-302C27E74DBC
https://kripta.biz/posts/198E0B2C-018C-41F6-89F7-302C27E74DBC
January 5, 2025 at 7:22 AM
Everybody can reply
Astellas Obtiene Aprobación de la Comisión Europea para VYLOY: Un Avance Esperanzador en el Tratamiento del Cáncer Gástrico Avanzado
https://eldinero.lat/posts/9A6B536D-0CBD-4082-815A-ED276B4F4131
https://eldinero.lat/posts/9A6B536D-0CBD-4082-815A-ED276B4F4131
January 5, 2025 at 7:22 AM
Everybody can reply
January 5, 2025 at 7:22 AM
Everybody can reply
[FiercePharma]Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy - FiercePharma After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer med Vyloy. | Astellas' Vyloy won an FDA approval to treat gastric...
October 20, 2024 at 5:15 PM
Everybody can reply
Breaking News: ( OTC: #ALPMY ) Astellas Receives Approval from the European Commission for VYLOY(TM) (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
#StockMarket #News
#StockMarket #News
September 20, 2024 at 5:40 PM
Everybody can reply
1 likes
Japanese pharmaco Astellas's gastric cancer drug, brand name Vyloy has been approved by the UK's health regulator. EU approval likely in October this year. It was approved in Japan in March 2024.
www.reuters.com/business/hea...
www.reuters.com/business/hea...
Astellas' gastric cancer therapy gets UK regulator's nod
Britain's health regulator said on Wednesday it has approved Japan-based Astellas Pharma's therapy to treat a type of gastric cancer.
www.reuters.com
August 16, 2024 at 9:24 AM
Everybody can reply
1 likes